Zelboraf

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG, Hoffmann-La Roche

Conditions

Advanced MalignanciesMalignant Melanoma

Phase 3

An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)

Active, not recruitingCTIS2023-506184-34-00

F. Hoffmann-La Roche AGAdvanced Malignancies

Start: 2019-08-09Target: 104Updated: 2025-11-10

Phase 4

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

CompletedNCT01898585

Hoffmann-La RocheMalignant Melanoma

Start: 2013-10-17End: 2019-05-22Updated: 2020-01-07